Skip to main content
. 2020 Feb 25;42(2):515–526. doi: 10.1007/s11096-020-00994-6

Fig. 4.

Fig. 4

Prospective assessment of DDIs and interventions advised by multidisciplinary team (MDT). HCV hepatitis C virus, CKD chronic kidney disease, HIV human immunodeficiency virus. Risk rating and relevant interventions; 1 = no known drug–drug interaction/no action needed, 2 = advice on monitoring or counselling given by pharmacist, 3 = concomitant drug regimen changed, 4 = DDI with HIV/HCV regimen requiring a change in the HIV regimen or additional monitoring requirements and 5 = HCV drug regimen changed